![]() ![]() In the COPD study, 97% of patients demonstrated correct use. On Day 28, patients were evaluated for correct use in a single attempt without additional instruction. At enrollment, patients were allowed up to 3 attempts to demonstrate correct use (with training between attempts 1 and 2, and 2 and 3, if necessary), and all patients were able to demonstrate correct use. Correct use was evaluated using instructions derived from the prescribing information for products delivered in the ELLIPTA inhaler. Inhalers did not contain active treatment.īoth studies were 28-day, open-label, placebo studies designed to assess ease of use of the ELLIPTA inhaler among adult patients who used the inhaler correctly on Day 28. One study was conducted in patients with COPD (N=266), and one study was conducted in patients with ASTHMA (N=250). See Dosage and Administration in the full Prescribing Information. For patients who do not respond adequately to TRELEGY 200 once daily, re-evaluate and consider other therapeutic regimens and additional therapeutic options. Maximum recommended dosage is 1 inhalation of TRELEGY 200 once daily.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |